+Compare
KRYS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
3.27B

KRYS Krystal Biotech Forecast, Technical & Fundamental Analysis

a biopharmaceutical company which provides therapies for rare and orphan diseases

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for KRYS with price predictions
08:00 PM EDT Sep 20, 2023

KRYS in downward trend: price dove below 50-day moving average on September 14, 2023

KRYS moved below its 50-day moving average on September 14, 2023 date and that indicates a change from an upward trend to a downward trend. In of 54 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 13, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on September 13, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for KRYS crossed bearishly below the 50-day moving average on September 18, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 230 cases where KRYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.008) is normal, around the industry mean (22.643). P/E Ratio (0.000) is within average values for comparable stocks, (131.410). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (308.526).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 32%. APLT experienced the highest price growth at 58%, while SEEL experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

KRYS is expected to report earnings to fall 4.00% to -120 cents per share on November 06

Krystal Biotech KRYS Stock Earnings Reports
Q3'23
Est.
$-1.20
Q2'23
Beat
by $0.02
Q1'23
Missed
by $0.33
Q4'22
Beat
by $0.01
Q3'22
Beat
by $0.02
The last earnings report on August 07 showed earnings per share of -125 cents, beating the estimate of -126 cents. With 30.49K shares outstanding, the current market capitalization sits at 3.27B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company which provides therapies for rare and orphan diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
2100 Wharton Street
Phone
+1 412 586-5830
Employees
210
Web
https://www.krystalbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FHYS22.42-0.09
-0.38%
Federated Hermes Short Duration HY ETF
PCY18.61-0.25
-1.33%
Invesco Emerging Markets Sov Debt ETF
SPYI47.38-0.69
-1.44%
NEOS S&P 500(R) High Income ETF
DKRB24.67-0.38
-1.51%
Subversive Decarbonization ETF
FMIL32.58-0.63
-1.89%
Fidelity® New Millennium ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XENE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+1.65%
XENE - KRYS
48%
Loosely correlated
-0.22%
ORMP - KRYS
48%
Loosely correlated
-5.80%
FOLD - KRYS
47%
Loosely correlated
-0.81%
CMRX - KRYS
45%
Loosely correlated
-0.95%
AVIR - KRYS
45%
Loosely correlated
N/A
More

Groups containing KRYS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+1.65%
orphan
(undefined stocks)
97%
Closely correlated
+0.15%
biopharmaceuticals
(undefined stocks)
59%
Loosely correlated
+0.33%
pharmaceuticals
(undefined stocks)
47%
Loosely correlated
-0.04%
therapy
(undefined stocks)
42%
Loosely correlated
-0.35%